Endotype-driven care pathways in patients with chronic rhinosinusitis Claus Bachert, MD, PhD, Nan Zhang, MD, PhD, Peter W. Hellings, MD, Jean Bousquet, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 141, Issue 5, Pages 1543-1551 (May 2018) DOI: 10.1016/j.jaci.2018.03.004 Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Endotypes of CRS and clinical consequences. Journal of Allergy and Clinical Immunology 2018 141, 1543-1551DOI: (10.1016/j.jaci.2018.03.004) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Therapeutic approaches according to endotypes. CRTH2, Chemoattractant receptor-homologous molecule expressed on TH2 cells; FESS, functional endoscopic sinus surgery; GCS, glucocorticosteroids. Journal of Allergy and Clinical Immunology 2018 141, 1543-1551DOI: (10.1016/j.jaci.2018.03.004) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Mechanisms of action of biologics in patients with CRSwNP. DC, Dendritic cell; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; Eos, eosinophils; EPO, eosinophil peroxidase; IL-4Rα, IL-4 receptor α; TSLP, thymic stromal lymphopoietin. Journal of Allergy and Clinical Immunology 2018 141, 1543-1551DOI: (10.1016/j.jaci.2018.03.004) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 ICPs for CRS (regional differences and new studies can lead to changes of the ICP). FESS, Functional endoscopic sinus surgery. Journal of Allergy and Clinical Immunology 2018 141, 1543-1551DOI: (10.1016/j.jaci.2018.03.004) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions